Curcumin loaded pH-sensitive nanoparticles for the treatment of colon cancer

Journal of Biomedical Nanotechnology

Volumn 5, Issue 5, 2009, Pages 445-455

  Prajakta, Dandekar ^a   Ratnesh, Jain ^a   Chandan, Kumar ^b   Suresh, Subramanian ^b   Grace, Samuel ^b   Meera, Venkatesh ^b   Vandana, Patravale ^a  

^a INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

^b BHABHA ATOMIC RESEARCH CENTRE   (India)

Author keywords

Colon cancer; Curcumin; MTT assay; pH sensitive; Polymeric nanoparticles

Indexed keywords

COLON CANCER; CURCUMIN; MTT ASSAYS; PH SENSITIVE; POLYMERIC NANOPARTICLES;

BIOCHEMISTRY; CELL CULTURE; EMULSIFICATION; ENCAPSULATION; POTENTIOMETRIC SENSORS;

NANOPARTICLES;

CURCUMIN; EUDRAGIT; NANOPARTICLE; POLYMER; SOLVENT;

ABSORPTION; ANALYTICAL PARAMETERS; ARTICLE; BIOAVAILABILITY; CANCER CELL CULTURE; CELL TRANSFER; COLON CANCER; CONCENTRATION (PARAMETERS); DRUG FORMULATION; EMULSION; ENCAPSULATION; EVAPORATION; FREEZE DRYING; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VIVO STUDY; MORPHOLOGY; PARTICLE SIZE; PH; SURFACE CHARGE;

ANTINEOPLASTIC AGENTS; CELL SURVIVAL; COLONIC NEOPLASMS; CRYSTALLIZATION; CURCUMIN; DRUG COMPOUNDING; HT29 CELLS; HUMANS; HYDROGEN-ION CONCENTRATION; MATERIALS TESTING; MOLECULAR CONFORMATION; NANOCAPSULES; NANOMEDICINE; PARTICLE SIZE; POLYMETHACRYLIC ACIDS; SURFACE PROPERTIES; TREATMENT OUTCOME;

EID: 76749136761     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2009.1038     Document Type: Article

References (44)

1. S. L. Parker, T. Tong, S. Bolden, and P. A. Wingo, Cancer statistics. CA Cancer J. Clin. 46, 5 (1996).
2. S. Gill and R. M. Goldberg, First-line treatment strategies to improve survival in patients with advanced colorectal cancer. Drugs 64, 27 (2004).
3. L. Saltz, The chemotherapy-naive patient with metastatic colorectal cancer. Community Oncology 4, 5 (2007).
4. J. K. Guddadarangavvanahally, J. M. R. Lingamullu, and K. S. Kunnumpurath, Improved HPLC method for the determination of curcumin, demethoxycurcumin and bisdemethoxycurcumin. J. Agric. Food Chem. 50, 3668 (2002).
5. C. A. C. Araújo and L. L. Leon, Biological activities of Curcuma longa L. Mem. Inst. Oswaldo. Cruz. 96, 723 (2001).
6. J. J. Johnson and H. Mukhtar, Curcumin for chemoprevention of colon cancer. Cancer Lett. 255, 170 (2007).
7. C. V. Rao, A. Rivenson, B. Simi, and B. S. Reddy, Chemoprevention of colon carcinogenesis by dietary curcumin, a naturally occurring plant phenolic compound. Cancer Res. 55, 259 (1995).
8. M. T. Huang, Y. R. Lou, W. Ma, H. L. Newmark, K. R. Reuhl, and A. H. Conney, Inhibitory effects of dietary curcumin on forestomach, duodenal, and colon carcinogenesis in mice. Cancer Res. 54, 5841 (1994).
9. D. P. Chauhan, Chemotherapeutic potential of curcumin for colorectal cancer. Curr. Pharm. Des. 8, 1695 (2002).
10. M. A. Pereira, C. J. Grubbs, L. H. Barnes, H. Li, G. R. Olson, I. Eto, M. Juliana, L. M. Whitaker, G. J. Kelloff , V. E. Steele, and R. A. Lubet, Effects of the phytochemicals, curcumin and quercetin, upon azoxymethane-induced colon cancer and 7,12-dimethylbenz[α]anthracene-induced mammary cancer in rats. Carcinogenesis 17, 1305 (1996).
11. T. Kawamori, R. Lubet, V. E. Steele, G. J. Kelloff, R. B. Kaskey, C. V. Rao, and B. S. Reddy, Chemopreventive effect of curcumin, a naturally occurring anti-inflammatory agent, during the promotion/progression stages of colon cancer. Cancer Res. 59, 597 (1999).
12. L. Tao, K. Li, and M. A. Pereira, Chemopreventive agents-induced regression of azoxymethane-induced aberrant crypt foci with the recovery of hexosaminidase activity. Carcinogenesis 18, 1415 (1997).
13. P. Anand, A. B. Kunnumakkara, R. A. Newman, and B. B. Aggarwal, Bioavailability of curcumin: Problems and promises. Mol. Pharm. 4, 807 (2007).
14. G. Shoba, D. Joy, T. Joseph, M. Majeed, R. Rajendran, and P. S. Srinivas, Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med. 64, 353 (1998).
15. M. Cruz-Correa, D. A. Shoskes, P. Sanchez, R. Zhao, L. M. Hylind, S. D. Wexner, and F. M. Giardiello, Combination treatment with curcumin and quercetin of adenomas in familial adenomatous polyposis. Clin. Gastroenterol. Hepatol. 4, 1035 (2006).
16. S. P. Verma, E. Salamone, and B. Goldin, Curcumin and genistein, plant natural products, show synergistic inhibitory effects on the growth of human breast cancer MCF-7 cells induced by estrogenic pesticides. Biochem. Biophys. Res. Commun. 233, 692 (1997).
17. L. Li, F. S. Braiteh, and R. Kurzrock, Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis. Cancer 104, 1322 (2005).
18. K. Maiti, K. Mukherjee, A. Gantait, B. Pada Saha, and P. K. Mukherjee, Curcumin-phospholipid complex: Preparation, therapeutic evaluation and pharmacokinetic study in rats. Int. J. Pharm. 330, 155163 (2007).
19. D. Suresh and K. Srinivasan, Studies on the in vitro absorption of spice principles-Curcumin, capsaicin and piperine in rat intestines. Food Chem. Toxicol. 45, 1437 (2007).
20. S. Bisht, G. Feldmann, S. Soni, R. Ravi, C. Karikar, A. Maitra, and A. Maitra, Polymeric nanoparticle-encapsulated curcumin ("nanocurcumin"): A novel strategy for human cancer therapy. J. Nanobiotechnol. 5, 1 (2007).
21. W. Tiyaboonchai, W. Tungpradit, and P. Plianbangchang, Formulation and characterization of curcuminoids loaded solid lipid nanoparticles. Int. J. Pharm. 337, 299 (2007).
22. A. Lamprecht and Y. Kawashima, pH-sensitive microparticles for oral drug delivery. J. Drug Del. Sci. Technol. 16, 26 (2006).
23. M. Rodríguez, J. L. Vila-Jato, and D. Torres, Design of a new multiparticulate system for potential site-specific and controlled drug delivery to the colonic region. J. Control. Release 55, 67 (1998).
24. W. M. Obeidat and J. C. Price, Preparation and evaluation of Eudragit S100 microspheres as pH-sensitive release preparations for piroxicam and theophylline using the emulsion-solvent evaporation method. J. Microencapsulation 23, 192 (2006).
25. P. P. Dandekar and V. B. Patravale, Development and validation of a stability-indicating LC method for curcumin. Chromatographia 69, 871 (2009).
26. F. Li, T. Wang, H. B. He, and X. Tang, The properties of bufadienolides-loaded nano-emulsion and submicro-emulsion during lyophilization. Int. J. Pharm. 349, 291 (2008).
27. D. D. Ankola, B. Viswanad, B. Bhardwaj, P. Ramarao, and M. N. V. Ravi Kumar, Development of potent oral nanoparticulate formulation of coenzyme Q10 for treatment of hypertension: Can the simple nutritional supplements be used as first line therapeutic agents for prophylaxis/therapy? Eur. J. Pharm. Biopharm 67, 361 (2007).
28. L. Montarini, F. Cilurzo, L. Valvo, A. Faucitano, A. Buttafava, A. Groppo, I. Genta, and B. Conti, Gamma irradiation effects on stability of poly(lactide-co-glycolide) microspheres containing clonazepam. J. Control. Release 75, 317 (2001).
29. R. Kinget, W. Kalala, L. Vervoort, and G. Van den Mooter, Colonic drug targeting. J. Drug Targeting 6, 129 (1998).
30. T. Minko, Drug targeting to the colon with lectins and neoglycoconjugates. Adv. Drug Deliv. Rev. 56, 491 (2004).
31. S. J. Doughlas, S. S. Davis, and L. Illum, Nanoparticles in drug delivery. CRC Crit. Rev. Ther. Drug 3, 233 (1987).
32. F. L. Grohmann, F. Csempesz, and M. Szogyi, Stabilization of small unilamellar DMPC-liposomes by uncharged polymers. Colloid. Polym. Sci. 276, 66 (1998).
33. I. Bala, V. Bhardwaj, S. Hariharan, J. Sitterberg, U. Bakowsky, and M. N. V. Ravi Kumar, Design of biodegradable nanoparticles: A novel approach to encapsulating poorly soluble phytochemical ellagic acid. Nanotechnology 16, 2819 (2005).
34. J. Vandervoort and A. Ludwig, Biocompatible stabilizers in the preparation of PLGA nanoparticles: A factorial design study. Int. J. Pharm. 238, 77 (2002).
35. S. Feng, Nanoparticle coating for drug delivery, U.S. Patent 20060188543, August 24 (2006).
36. Z. Zang and S. S. Feng, The drug encapsulation efficiency, in vitro drug release, cellular uptake and cytotoxicity of paclitaxel-loaded poly(lactide)-tocopheryl polyethylene glycol succinate nanoparticles. Biomaterials 27, 4025 (2006).
37. Y. C. Dong and S. S. Feng, Methoxy poly(ethylene glycol)-poly(lactide) (MPEG-PLA) nanoparticles for controlled delivery of anticancer drugs. Biomaterials 25, 2843 (2004).
38. A. S. Pattani, S. D. Mandawgade, and V. B. Patravale, Development and comparative anti-microbial evaluation of lipid nanoparticles and nanoemulsion of polymyxin B. J. Nanosci. Nanotech. 6, 2986 (2006).
39. S. S. Feng, L. Mu, B. H. Chen and D. Pack, Polymeric nanospheres fabricated with natural emulsifiers for clinical administration of an anticancer drug paclitaxel (Taxol®). Mat. Sci. Eng. C 20, 85 (2002).
40. L. Mu and S. S. Feng, Fabrication, characterization and in vitro release of paclitaxel (Taxol®) loaded poly(lactic-co-glycolic acid) microspheres prepared by spray drying technique with lipid/cholesterol emulsifiers. J. Control. Release 76, 239 (2001).
41. L. Mu and S. S. Feng, Vitamin E TPGS used as emulsifier in the solvent evaporation/extraction technique for fabrication of polymeric nanospheres for controlled release of paclitaxel (Taxol®). J. Control. Release 80, 129 (2002).
42. A. Goel, C. R. Boland, and D. P. Chauhan, Specific inhibition of cyclooxygenase-2 (COX-2) expression by dietary curcumin in HT-29 human colon cancer cells. Cancer Lett. 172, 111 (2001).
43. T. Mosmann, Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65, 55 (1983).
44. N. Cao and S. S. Feng, Doxorubicin conjugated to d-α-tocopheryl polyethylene glycol 1000 succinate (TPGS): Conjugation chemistry, characterization, in vitro and in vivo evaluation. Biomaterials 29, 3856 (2008).